Literature DB >> 18313539

Syndromic colon cancer: lynch syndrome and familial adenomatous polyposis.

Tusar K Desai1, Donald Barkel.   

Abstract

Colon cancer, the third leading cause of mortality from cancer in the United States, afflicts about 150,000 patients annually. More than 10% of these patients exhibit familial clustering. The most common and well characterized of these familial colon cancer syndromes is hereditary nonpolyposis colon cancer syndrome (Lynch syndrome), which accounts for about 2% to 3% of all cases of colon cancer in the United States. We review the current knowledge of familial cancer syndromes, with an emphasis on Lynch syndrome and familial adenomatous polyposis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18313539     DOI: 10.1016/j.gtc.2007.12.006

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  9 in total

Review 1.  Genetic architecture of colorectal cancer.

Authors:  Ulrike Peters; Stephanie Bien; Niha Zubair
Journal:  Gut       Date:  2015-07-17       Impact factor: 23.059

2.  Performance of Lynch syndrome predictive models in a multi-center US referral population.

Authors:  Omar Khan; Amie Blanco; Peggy Conrad; Cassandra Gulden; Tovah Z Moss; Olufunmilayo I Olopade; Sonia S Kupfer; Jonathan Terdiman
Journal:  Am J Gastroenterol       Date:  2011-07-12       Impact factor: 10.864

3.  Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma.

Authors:  Jonathan S L Earle; Rajyalakshmi Luthra; Angela Romans; Ronald Abraham; Joe Ensor; Hui Yao; Stanley R Hamilton
Journal:  J Mol Diagn       Date:  2010-04-22       Impact factor: 5.568

4.  The association of NAT1 polymorphisms and colorectal carcinoma risk: evidence from 20,000 subjects.

Authors:  Jie Cai; Yang Zhao; Chang Le Zhu; Jun Li; Zu Hu Huang
Journal:  Mol Biol Rep       Date:  2012-02-11       Impact factor: 2.316

5.  The impact of family history on the outcome of patients with colorectal cancer in a veterans' hospital.

Authors:  Ping-Sheng Kao; Jen-Kou Lin; Huann-Sheng Wang; Shung-Haur Yang; Jeng-Kai Jiang; Wei-Shone Chen; Tzu-Chen Lin; Anna Fen-Yau Li; Wen-Yi Liang; Shih-Ching Chang
Journal:  Int J Colorectal Dis       Date:  2009-07-21       Impact factor: 2.571

6.  Absence of association between N-acetyltransferase 2 acetylator status and colorectal cancer susceptibility: based on evidence from 40 studies.

Authors:  Lou qian Zhang; Jian nong Zhou; Jun Wang; Guo dong Liang; Jing ying Li; Yi dan Zhu; Yun tao Su
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

Review 7.  Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer.

Authors:  Shunsuke Kato
Journal:  Diagnostics (Basel)       Date:  2021-02-06

8.  Methionine synthase A2756G polymorphism and risk of colorectal adenoma and cancer: evidence based on 27 studies.

Authors:  Weixing Ding; Dong-Lei Zhou; Xun Jiang; Lie-Sheng Lu
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

9.  Mouse models of gastric cancer.

Authors:  Yoku Hayakawa; James G Fox; Tamas Gonda; Daniel L Worthley; Sureshkumar Muthupalani; Timothy C Wang
Journal:  Cancers (Basel)       Date:  2013-01-24       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.